|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this study suggests that down-regulation of KAI1/CD82 mRNA expression in human melanoma cell lines is related to LOH or allelic imbalance, but not to methylation of the KAI1/CD82 gene region.
|
19082457 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To reveal the effect of KAI1 on the in vivo metastasis of tumors other than prostatic cancer, we transfected a human KAI1 cDNA into highly metastatic B16-BL6 murine melanoma cells and established stable transfectant clones with different expression levels of KAI1 message.
|
9617345 |
1998 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In fact, KAI1 expression is drastically reduced in primary melanoma compared with dysplastic nevi (P = 1.8×10(-4)) and further reduced in metastatic melanoma compared with primary melanoma (P = 9.4 × 10(-15)).
|
24130172 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results showed that CD82 expression inhibited melanoma cell-induced gap formation, melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo.
|
23873025 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The relationship between down-regulation of KAI1/CD82 mRNA expression and KAI1/CD82 gene alterations in human melanoma cell lines were investigated.
|
19082457 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of KAI1 protein may be an indicator of metastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas.
|
9671393 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transmembrane 4 superfamily member KAI1 (CD82) has been shown to inhibit pulmonary metastases in experimental metastasis models of prostate cancer and melanoma.
|
10582691 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD82 has been implicated as a possible prostate cancer metastasis suppressor gene, whereas CD63 is involved in the progression of human melanoma cancer.
|
15375577 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, U2AF2 is a downstream target of CD82 and in malignant melanoma facilitates CD44v8-10 alternative splicing.
|
27041584 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggested that KAI1 was able to suppress melanoma angiogenesis by downregulating IL-6 and VEGF expression, and the restoration of KAI1 functionality offered a new approach in human melanoma treatment.
|
26199094 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, compared to KAI1 and p27 as an individual prognostic marker, the combined signature is more closely associated with melanoma patient survival (P = 0.025, 0.264 and 0.009, respectively).
|
26246476 |
2015 |